1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Australia Pharmaceuticals and Healthcare Report Q1 2016

Australia Pharmaceuticals and Healthcare Report Q1 2016

  • November 2015
  • -
  • Business Monitor International
  • -
  • 107 pages

Includes 3 FREE quarterly updates

BMI View: The prevailing trend of austerity targeting pharmaceuticals and healthcare spending inAustralia will continue to weigh on the country's attractiveness to innovative drugmakers. On top of this,ongoing political instability and policy uncertainty have moderated the confidence to invest in Australia,with cooperation between the government and the pharmaceutical industry remaining sparse as theirrelations come under strain. Meanwhile, although the Trans-Pacific Partnership's latest outcome confirmsAustralia's attempt to balance incentives to innovation in the biopharmaceutical industry with costcontainment concerns, the recent creation of a medical-research fund will provide some level of governmentsupport for research and innovation initiatives in the sector, albeit under a gradual and phased multi-yearhorizon.

Headline Expenditure Projections

? Pharmaceuticals: AUD13.48bn (USD12.15bn) in 2014 to AUD13.99bn (USD10.35bn) in 2015; +3.7%in local currency terms and -14.8% in US dollar terms, due to significant exchange ratefluctuations. Forecast in line with last quarter.

Table Of Contents

Australia Pharmaceuticals and Healthcare Report Q1 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (2013-2019) 7
SWOT 10
Industry Forecast 12
Pharmaceutical Market Forecast 12
Table: Pharmaceutical Sales, Historical Data And Forecasts (Australia 2011-2019) 15
Healthcare Market Forecast 16
Table: Selected Health Measures In Australia FY2015/16 Budget 17
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Australia 2011-2019) 19
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Australia 2011-2019) 19
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Australia 2011-2019) 20
Prescription Drug Market Forecast 21
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Australia 2011-2019) 23
Patented Drug Market Forecast 24
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Australia 2011-2019) 26
Generic Drug Market Forecast 27
Table: Cost Of Selected Drugs Post-Price Disclosure, April 2013 30
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Australia 2011-2019) 30
OTC Medicines Market Forecast 31
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Australia 2011-2019) 33
Pharmaceutical Trade Forecast 34
Table: Pharmaceutical Trade Data And Forecasts (Australia 2013-2019) 35
Table: Pharmaceutical Trade Data And Forecasts local currency (Australia 2013-2019) 36
Industry Risk Reward Index 37
Asia Pacific Risk/Reward Index 37
Australia Risk/Reward Index 44
Rewards 44
Risks 45
Regulatory Review 46
Table: EU and ICH Guidelines Adopted In The TGA's Biosimilars Guidance Document 47
Intellectual Property Issues 50
Pricing and Reimbursement Regime 54
Table: Selected Drugs Undergoing SPD (AUD) 55
Table: Historical PBS Co-Payments 56
Table: New PBS Formularies 60
Market Overview 61
Healthcare Sector 61
Research And Development 63
Clinical Trials 65
Epidemiology 66
Competitive Landscape 69
Research-Based Industry 69
Company Developments 70
Table: Multinational Market Activity 71
Pharmaceutical Distribution 72
Company Profile 74
Australian Pharmaceutical Industries 74
CSL 77
GlaxoSmithKline 81
Mayne Pharma Group 85
Sanofi 89
Sigma 92
Demographic Forecast 96
Table: Population Headline Indicators (Australia 1990-2025) 97
Table: Key Population Ratios (Australia 1990-2025) 97
Table: Urban/Rural Population and Life Expectancy (Australia 1990-2025) 98
Table: Population By Age Group (Australia 1990-2025) 98
Table: Population By Age Group % (Australia 1990-2025) 99
Glossary 101
Methodology 103
Pharmaceutical Expenditure Forecast Model 103
Healthcare Expenditure Forecast Model 103
Notes On Methodology 104
Risk/Reward Index Methodology 105
Index Overview 106
Table: Pharmaceutical Risk/Reward Index Indicators 106
Indicator Weightings 107

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025 Summary Atrial fibrillation (AF) is the most common cardiac arrhythmia and is a heart condition that causes an irregula ...

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025 Summary Venous thromboembolism (VTE) is a disease that includes a myriad of life-threatening disorders ranging from ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.